Vanguard Total International Stock Index Fund ETF vs Zoetis Inc — how do they compare? Vanguard Total International Stock Index Fund ETF trades at $87.5, while Zoetis Inc trades at $75.11 (market cap $30.92B). The key difference: Zoetis Inc pays a 2.83% dividend while Vanguard Total International Stock Index Fund ETF pays none, and Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| VXUS | ZTS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $87.21 | $156.76 |
52-Week Low | $70.87 | $71.91 |
Market Cap | — | $30.92B |
Enterprise Value | — | $38.49B |
Dividend Yield | — | 2.83% |
Signals from Pluang's Aura AI — not financial advice
VXUS trades at $87.21, up 1.03% with strong bullish technical signals from moving averages. The ETF offers broad international diversification with over 8,700 non-U.S. stocks, recently delivering 27.82% total returns over the past year according to Seeking Alpha (August 8, 2026). Institutional interest is growing with multiple firms increasing positions, while analysts highlight its valuation discount to U.S. equities.
The outlook remains positive given international diversification benefits and institutional accumulation, though RSI levels suggest potential near-term consolidation. Key risks include global economic volatility and currency fluctuations. Wall Street sentiment leans bullish with Seeking Alpha maintaining a Buy rating, supported by the ETF's low expense ratio and comprehensive market exposure.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →